RecruitingRecruiting
Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients
NCT07271420 · Chinese University of Hong Kong
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This prospective, single-center treatment-withdrawal crossover study enrolled 10 patients on chronic peritoneal dialysis (PD) and uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg).
Following written informed consent, participants entered the treatment arm, receiving oral hydrochlorothiazide once daily on top of their standard of treatment for 90 days. This was followed by a 14-day washout period, after which participants entered a 90-day control period.
Eligibility criteria
Inclusion Criteria:
* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg)
Exclusion Criteria:
* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months
Study design
Enrollment target: 40 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2020-01-01
Estimated completion: 2027-06-30
Last updated: 2025-12-09
Interventions
Drug: Hydrochlorothiazide 25mg once per day
Primary outcomes
- • Change in systolic and diastolic blood pressure (90 days)
Sponsor
Chinese University of Hong Kong · other
Contacts & investigators
ContactGordon Chan, MD, MRCP · contact · cck295@ha.org.hk · 0085235052211
All locations (1)
Prince of Wales Hospital. The Chinese University of Hong KongRecruiting
Hong Kong, Hong Kong